- Home
- Publications
- Publication Search
- Publication Details
Title
Current status of immunotherapy
Authors
Keywords
-
Journal
JAPANESE JOURNAL OF CLINICAL ONCOLOGY
Volume 46, Issue 3, Pages 191-203
Publisher
Oxford University Press (OUP)
Online
2016-01-28
DOI
10.1093/jjco/hyv201
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Phase Ia Study of FoxP3+ CD4 Treg Depletion by Infusion of a Humanized Anti-CCR4 Antibody, KW-0761, in Cancer Patients
- (2015) K. Kurose et al. CLINICAL CANCER RESEARCH
- Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial
- (2015) Robert J. Motzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab
- (2015) David F. McDermott et al. JOURNAL OF CLINICAL ONCOLOGY
- Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer
- (2015) Scott N. Gettinger et al. JOURNAL OF CLINICAL ONCOLOGY
- Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
- (2015) Dirk Schadendorf et al. JOURNAL OF CLINICAL ONCOLOGY
- Immune Checkpoint Blockade in Cancer Therapy
- (2015) Michael A. Postow et al. JOURNAL OF CLINICAL ONCOLOGY
- The interaction of anticancer therapies with tumor-associated macrophages
- (2015) Alberto Mantovani et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
- (2015) Jeffrey S Weber et al. LANCET ONCOLOGY
- Combination cancer immunotherapy and new immunomodulatory targets
- (2015) Kathleen M. Mahoney et al. NATURE REVIEWS DRUG DISCOVERY
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
- (2015) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- (2015) Edward B. Garon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sialyl Lewis x (CD15s) identifies highly differentiated and most suppressive FOXP3highregulatory T cells in humans
- (2015) Makoto Miyara et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients
- (2015) Emanuela Romano et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The future of immune checkpoint therapy
- (2015) P. Sharma et al. SCIENCE
- Identification and Characterization of MEDI4736, an Antagonistic Anti-PD-L1 Monoclonal Antibody
- (2015) R. Stewart et al. Cancer Immunology Research
- Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells
- (2015) B. Boyerinas et al. Cancer Immunology Research
- Inhibitory Receptors Beyond T Cell Exhaustion
- (2015) Silvia A. Fuertes Marraco et al. Frontiers in Immunology
- High FoxP3 expression in tumour cells predicts better survival in gastric cancer and its role in tumour microenvironment
- (2014) G-F Ma et al. BRITISH JOURNAL OF CANCER
- Chemotherapeutic Targeting of Cancer-Induced Immunosuppressive Cells
- (2014) D. Alizadeh et al. CANCER RESEARCH
- Tumor-Associated Macrophages: From Mechanisms to Therapy
- (2014) Roy Noy et al. IMMUNITY
- Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
- (2014) Suzanne L. Topalian et al. JOURNAL OF CLINICAL ONCOLOGY
- Imatinib Mesylate Inhibits CD4+CD25+ Regulatory T Cell Activity and Enhances Active Immunotherapy against BCR-ABL- Tumors
- (2014) N. Larmonier et al. JOURNAL OF IMMUNOLOGY
- MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
- (2014) Thomas Powles et al. NATURE
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- (2014) Roy S. Herbst et al. NATURE
- Detection of self-reactive CD8+T cells with an anergic phenotype in healthy individuals
- (2014) Yuka Maeda et al. SCIENCE
- The Path to Reactivation of Antitumor Immunity and Checkpoint Immunotherapy
- (2014) H.-J. Kim et al. Cancer Immunology Research
- High expression of FOXP3 in primary melanoma is associated with tumour progression
- (2013) A.L. Gerber et al. BRITISH JOURNAL OF DERMATOLOGY
- Doxorubicin Eliminates Myeloid-Derived Suppressor Cells and Enhances the Efficacy of Adoptive T-Cell Transfer in Breast Cancer
- (2013) D. Alizadeh et al. CANCER RESEARCH
- Stevens-Johnson Syndrome associated with mogamulizumab treatment of adult T-cell leukemia / lymphoma
- (2013) Takashi Ishida et al. CANCER SCIENCE
- Polarization profiles of human M-CSF-generated macrophages and comparison of M1-markers in classically activated macrophages from GM-CSF and M-CSF origin
- (2013) Marie Jaguin et al. CELLULAR IMMUNOLOGY
- Molecular Pathways: Coexpression of Immune Checkpoint Molecules: Signaling Pathways and Implications for Cancer Immunotherapy
- (2013) C. J. Nirschl et al. CLINICAL CANCER RESEARCH
- Development and Maintenance of Regulatory T cells
- (2013) Naganari Ohkura et al. IMMUNITY
- Oncology Meets Immunology: The Cancer-Immunity Cycle
- (2013) Daniel S. Chen et al. IMMUNITY
- Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma
- (2013) Tyler R. Simpson et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial
- (2013) Jason R Westin et al. LANCET ONCOLOGY
- Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
- (2013) Omid Hamid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans
- (2013) D. Sugiyama et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Cancer Immunotherapy
- (2013) J. Couzin-Frankel SCIENCE
- Natural and Induced T Regulatory Cells in Cancer
- (2013) Dennis O. Adeegbe et al. Frontiers in Immunology
- Antitumor T-cell responses contribute to the effects of dasatinib on c-KIT mutant murine mastocytoma and are potentiated by anti-OX40
- (2012) Y. Yang et al. BLOOD
- Abstract 3439: Tissue tranglutaminase (TG2) targeting by multifunctional field responsive gold nanoparticles
- (2012) Jordan Schmitt et al. CANCER RESEARCH
- VEGFA-VEGFR Pathway Blockade Inhibits Tumor-Induced Regulatory T-cell Proliferation in Colorectal Cancer
- (2012) M. Terme et al. CANCER RESEARCH
- Tax is a potential molecular target for immunotherapy of adult T-cell leukemia/lymphoma
- (2012) Susumu Suzuki et al. CANCER SCIENCE
- T Cell Receptor Stimulation-Induced Epigenetic Changes and Foxp3 Expression Are Independent and Complementary Events Required for Treg Cell Development
- (2012) Naganari Ohkura et al. IMMUNITY
- Low-dose gemcitabine depletes regulatory T cells and improves survival in the orthotopic Panc02 model of pancreatic cancer
- (2012) Ivan Shevchenko et al. INTERNATIONAL JOURNAL OF CANCER
- Defucosylated Anti-CCR4 Monoclonal Antibody (KW-0761) for Relapsed Adult T-Cell Leukemia-Lymphoma: A Multicenter Phase II Study
- (2012) Takashi Ishida et al. JOURNAL OF CLINICAL ONCOLOGY
- Inhibitory Receptors on Lymphocytes: Insights from Infections
- (2012) P. M. Odorizzi et al. JOURNAL OF IMMUNOLOGY
- Paclitaxel promotes differentiation of myeloid-derived suppressor cells into dendritic cellsin vitroin a TLR4-independent manner
- (2012) Tillmann Michels et al. Journal of Immunotoxicology
- Regulatory T cells in melanoma: the final hurdle towards effective immunotherapy?
- (2012) Joannes FM Jacobs et al. LANCET ONCOLOGY
- Immunotherapy of Cancer with 4-1BB
- (2012) D. S. Vinay et al. MOLECULAR CANCER THERAPEUTICS
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lack of B and T lymphocyte attenuator exacerbates autoimmune disorders and induces Fas-independent liver injury in MRL-lpr/lpr mice
- (2011) Y. Oya et al. INTERNATIONAL IMMUNOLOGY
- Prognostic potential of FOXP3 expression in non-small cell lung cancer cells combined with tumor-infiltrating regulatory T cells
- (2011) Hiroyuki Tao et al. LUNG CANCER
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
- (2011) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dendritic Cell Vaccination in Combination with Anti-CD25 Monoclonal Antibody Treatment: A Phase I/II Study in Metastatic Melanoma Patients
- (2010) J. F. M. Jacobs et al. CLINICAL CANCER RESEARCH
- A Novel Chemoimmunomodulating Property of Docetaxel: Suppression of Myeloid-Derived Suppressor Cells in Tumor Bearers
- (2010) K. N. Kodumudi et al. CLINICAL CANCER RESEARCH
- Macrophages, innate immunity and cancer: balance, tolerance, and diversity
- (2010) Alberto Mantovani et al. CURRENT OPINION IN IMMUNOLOGY
- The biology of myeloid-derived suppressor cells: The blessing and the curse of morphological and functional heterogeneity
- (2010) Je-In Youn et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Selective Impairment of CD4+CD25+Foxp3+Regulatory T cells by paclitaxel is explained by Bcl-2/Bax mediated apoptosis
- (2010) Nan Liu et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Sorafenib reduces the percentage of tumour infiltrating regulatory T cells in renal cell carcinoma patients
- (2010) Ingrid M.E. Desar et al. INTERNATIONAL JOURNAL OF CANCER
- A Decrease of Regulatory T Cells Correlates With Overall Survival After Sunitinib-based Antiangiogenic Therapy in Metastatic Renal Cancer Patients
- (2010) Olivier Adotevi et al. JOURNAL OF IMMUNOTHERAPY
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Stromal regulatory T-cells are associated with a favourable prognosis in gastric cancer of the cardia
- (2009) Matthias Haas et al. BMC GASTROENTEROLOGY
- Intratumoral CD8+ T/FOXP3+ cell ratio is a predictive marker for survival in patients with colorectal cancer
- (2009) Hiroyuki Suzuki et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Sunitinib Inhibition of Stat3 Induces Renal Cell Carcinoma Tumor Cell Apoptosis and Reduces Immunosuppressive Cells
- (2009) H. Xin et al. CANCER RESEARCH
- Increased Intratumoral FOXP3-positive Regulatory Immune Cells during Interleukin-2 Treatment in Metastatic Renal Cell Carcinoma
- (2009) H. K. Jensen et al. CLINICAL CANCER RESEARCH
- Sunitinib Mediates Reversal of Myeloid-Derived Suppressor Cell Accumulation in Renal Cell Carcinoma Patients
- (2009) J. S. Ko et al. CLINICAL CANCER RESEARCH
- Functional Delineation and Differentiation Dynamics of Human CD4+ T Cells Expressing the FoxP3 Transcription Factor
- (2009) Makoto Miyara et al. IMMUNITY
- CD27 sustains survival of CTLs in virus-infected nonlymphoid tissue in mice by inducing autocrine IL-2 production
- (2009) Victor Peperzak et al. JOURNAL OF CLINICAL INVESTIGATION
- FOXP3 Expression and Overall Survival in Breast Cancer
- (2009) Andrea Merlo et al. JOURNAL OF CLINICAL ONCOLOGY
- The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells
- (2008) Christine Galustian et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Incidence and Prognostic Impact of FoxP3+ Regulatory T Cells in Human Gliomas
- (2008) A. B. Heimberger et al. CLINICAL CANCER RESEARCH
- Differential impairment of regulatory T cells rather than effector T cells by paclitaxel-based chemotherapy
- (2008) Lei Zhang et al. CLINICAL IMMUNOLOGY
- Tumor-Infiltrating FOXP3+ T Regulatory Cells Show Strong Prognostic Significance in Colorectal Cancer
- (2008) Paul Salama et al. JOURNAL OF CLINICAL ONCOLOGY
- Regulation of CD28 expression on CD8+ T cells by CTLA-4
- (2007) M. Berg et al. JOURNAL OF LEUKOCYTE BIOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now